$Eli Lilly(LLY.US) This wave is a standard emotional rollercoaster. On earnings day, it directly rose by over 10%, then dropped by over 7% the next day, and now it's rebounding by over 4% in pre-market. The fundamentals haven't suddenly worsened, but Trump's statement "Eli Lilly promises to significantly reduce GLP-1 costs" directly brought pricing power and policy risks to the forefront. This stock is no longer just a pure pharmaceutical play—it's a combination of policy, sentiment, and capital speculation.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
